Ingenium Therapeutics
Daejeon
About Ingenium Therapeutics
Ingenium Therapeutics commercializes NK anti-cancer immunotherapy with clinical impact based on solid basic research.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $9.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2023)
- Website: ingeniumcell.co.kr
Industries & Categories
Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/ingenium-therapeutics-25355 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.